United States


UCB.BR on Brussels Stock Exchange

24 Mar 2017
Change (% chg)

€0.04 (+0.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

UCB FY revenue, operating profit ahead of Reuters poll
Thursday, 23 Feb 2017 01:12am EST 

UCB SA : Reports FY revenue of 4.18 billion euros ($4.42 billion) versus 4.12 billion euros in Reuters poll . FY Cimzia sales 1.31 billion euros versus 1.28 billion euros in Reuters poll . FY Vimpat sales 814 million euros versus 798 million euros in reuters poll . Fy Keppra sales 724 million euros versus 696 million euros in Reuters poll . Fy Neupro sales 302 million euros versus 296 million euros in Reuters poll . FY REBIT 796 million euros versus 748 million euros in Reuters poll . FY net profit group share 520 million euros versus 623 million euros a year ago . Board of directors of ucb proposes a dividend of 1.15 euros per share (gross), an increase by five eurocents or by 4.5 pct . UCB expects 2017 revenue to reach 4.25-4.35 billion euros; recurring Ebitda should increase to 1.15–1.20 billion euros .2017 core earnings per share are expected in the range of 3.70–4.00 euros based on an expected average of 188 million shares outstanding.  Full Article

UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures
Thursday, 19 Jan 2017 12:00pm EST 

UCB SA :UCB files Briviact (brivaracetam) CV in the US as monotherapy treatment for adult epilepsy patients with partial-onset seizures.  Full Article

Final CIMZIA Phase 3 trial meets primary efficacy endpoint
Thursday, 19 Jan 2017 02:12am EST 

Dermira Inc : Final CIMZIA® (Certolizumab Pegol) phase 3 trial meets primary efficacy endpoint in patients with moderate-to-severe chronic Plaque Psoriasis . Says UCB intends to submit marketing applications to regulatory authorities in Q3 of 2017 .Dermira Inc - CIMZIA demonstrated statistically significant improvements for all primary or co-primary endpoints compared to placebo.  Full Article

UCB announces EU approval for Vimpat as monotherapy
Tuesday, 20 Dec 2016 01:06am EST 

UCB SA : Vimpat EU monotherapy approval . European commission approved license extension for Vimpat (lacosamide) for use as monotherapy in treatment of partial-onset seizures in adult and adolescent patients with epilepsy .Approval comes into immediate effect.  Full Article

UCB and Amgen seek marketing approval of romosozumab in Japan
Monday, 19 Dec 2016 07:00pm EST 

UCB SA :Says Amgen and UCB announce submission of application for investigational osteoporosis medication romosozumab in Japan.  Full Article

Evogen and UCB announce collaboration for EvoScore Start
Monday, 5 Dec 2016 07:00am EST 

UCB SA :Evogen and UCB announce collaboration for further development of EvoScore START for improved diagnosis of epilepsy.  Full Article

Amgen and UCB say FDA accepts biologics license application for romosozumab
Monday, 26 Sep 2016 04:00pm EDT 

Amgen Inc : Amgen and UCB announce FDA acceptance of biologics license application for romosozumab .Amgen says FDA has set a prescription drug user fee act (pdufa) target action date of July 19, 2017, for romosozumab.  Full Article

UCB says Delaware court confirms validity Vimpat patent
Monday, 15 Aug 2016 02:49am EDT 

UCB SA : Announced on Sunday that the Delaware District Court confirmed the validity of U.S. patent RE38,551 related to Vimpat .Decision is currently under seal and will be released following an order from the court.  Full Article

Financiere de Tubize H1 profit at 106.4 million euros
Thursday, 28 Jul 2016 02:14am EDT 

Financiere De Tubize Sa : Dividend received from UCB: 74.9 million euros ($82.94 million) . Decreasing debt from 286.3 million euros at 31 December 2015 to 238.0 million euros at 30 June 2016 .H1 profit (consolidated) of 106.4 million euros.  Full Article

UCB H1 profit of group up at 316 million euros
Thursday, 28 Jul 2016 01:03am EDT 

UCB Sa : Financial outlook 2016 confirmed . H1 gross profit increased to 1.45 billion euros ($497.93 million) (+6 pct, +4 pct cer) . H1 revenue and net sales increased to 2.0 billion euros(+5 pct; +5 pct cer) and 1.9 billion euros(+10 pct; +9 pct cer) respectively driven by continued core product growth . H1 underlying profitability -recurring EBITDA- reached 549 million euros (+18 pct; +11 pct cer) .H1 profit of group was 316 million euros(+9 pct; 0 pct cer) of which 300 million euros is attributable to UCB shareholders and 16 million euros to non-controlling interests.  Full Article

More From Around the Web

Ex-UCB executive loses bid to seal whistleblower lawsuit

A federal judge has denied a former UCB SA executive's request to keep a whistleblower lawsuit he filed against the drug company under seal, rejecting his argument that he may face retaliation from his new employer once his identity becomes public.